In the treatment of type 2 diabetes, along with diet and exercise, INVOKAMET® XR and INVOKAMET® (canagliflozin/metformin HCl) can

awaken a transformation

Consider once-daily INVOKAMET® XR, featuring similar technology to Glumetza®1-3*

*The metformin XR layer of all INVOKAMET® XR doses contains Acuform® technology—the same XR delivery system as Glumetza® 500 mg.

Indicated trademarks are registered trademarks of their respective owners.

There have been no clinical efficacy studies conducted with INVOKAMET® XR or INVOKAMET®. The efficacy and safety of INVOKAMET® XR were assessed in a clinical study as initial combination of canagliflozin and metformin XR coadministered as individual tablets.1,4,6

Bioequivalence of INVOKAMET® XR to canagliflozin and metformin XR and of INVOKAMET® to canagliflozin and metformin coadministered as individual tablets was demonstrated in healthy subjects.1,6

References: 1. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Depomed licenses Glumetza® data and Acuform® technology [press release]. Newark, CA: Depomed, Inc.; August 5, 2010. 3. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 4. Rosenstock J, Chuck L, González-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care. 2016;39(3):353-362. 5. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-2592. Supplemental tables available at: Accessed May 16, 2018. 6. INVOKAMET® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.